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Patient-reported outcomes (PROs) are accepted endpoints in the
evaluation of patient treatment. Attention has focused on deﬁning
the minimal clinically important improvement/change (MCID) of
PROs as a way to identify response to treatment. Importantly, the
number needed to treat that is commonly used in similar circum-
stances is based on the responder rate.
Goldsmith et al. introduced the concept of the MCID based on
expert clinical opinion in 19931. Subsequently, Jaeschke et al.2
deﬁned the MCID as “.the smallest difference in score in the
domain of interest that patients perceive as beneﬁcial and which
would mandate, in the absence of troublesome side effects and
excessive cost, a change in the patient’s management.” Their
methods included the use of a patient global rating where the
patient indicates how much better or worse they perceive they areA.M. Davis, MP-11, Room 322,
et, Toronto, ON, Canada M5T
s).
s Research Society International. Pon a scale ranging from 7, a great deal worse to þ7, a great deal
better. The mean score of those who rated themselves as þ1, a little
better, were perceived to have achieved a MCID. This has been
labelled the anchor-based approach. Other authors have slightly
different deﬁnitions of clinically important difference3 and still
others have used variations of the anchor-based approach4. The
recent Federal Drug Administration guidelines for PROs afﬁrmed
that anchor-based methodology was required in reporting the
proportion responding to treatment in the evaluation of all medical
devices and drugs5. A recent review by King details the deﬁnitions
and methods for determining the MCID4.
It is accepted that a PRO does not have a single MCID but rather
that it is an interaction of the outcome measure and the context in
which it is used. As such, a given PRO has a range of MCIDs and the
value varies depending on the patient group and the intervention4.
Additionally, as reviewed by King4 several authors have identiﬁed
methodological challenges in determining important change. These
challenges include but are not limited to reported values for
important change that are less than measurement error6 and vari-
ability in the magnitude of perceived important change depending
on the baseline score7. However, authors have reported all of thoseublished by Elsevier Ltd. All rights reserved.
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responders without considering whether the MCID was not ach-
ieved due to a ceiling effect. Further, the potential inﬂuence of
regression to themeanphenomenonhasnot been consideredRecent
studies of cohorts of hip8 and knee replacement9 are examples.
Much of the developmental work and application of MCID has
been in the context of clinical trials2e4. As such, this work has
occurred in the context of pre-speciﬁed eligibility criteria, often
inclusive of a threshold score for the PRO that will be used as the
outcome. Recently, researchers also have deﬁned responders and
evaluated factors associatedwith achievingMCID in patient cohorts
where such eligibility criteria have not been used8,9. These works
have not considered howbaseline scores less than themagnitude of
the MCID impact interpretation of response. We here illustrate in
a group of people with total knee replacement (TKR) for osteoar-
thritis (OA) that, in such cohort studies, there are people who
respond, those who do not respond and a third group who are
misclassiﬁed as non-responders because their baseline score does
not allow achievement of important change.
Methods, results and discussion
To illustrate the impact of classifying as non-responders those
who cannot achieve a MCID due to their pre-intervention PRO
score, we chose a cohort of people who had primary TKR for OA.
TKR has been shown to be an effective surgical procedure, with
a low complication rate, for relieving pain and improving function
in people with moderate to severe knee OA when medical
management has failed10. The Western Ontario McMaster Univer-
sities’ Osteoarthritis Outcome Measure (WOMAC) is a commonly
used PRO measure in this patient group. This work used the
WOMAC Likert version 3.0 pain and function subscales, scored
0e20 and 0e68 respectively with 0 representing no pain or func-
tional difﬁculties respectively, as a clinically important difference
value for the subscales has been published for people having TKR in
the geographic region of our sample11. Similar conﬁrmatory data
from Spain have been published12.
The presentwork focuses on theWOMAC pain and function data
from pre-surgery and 12 months post-surgery from a sample of 494
people who had TKR; 483 of these had pre-surgery and 1 year
WOMAC pain scores and 486 had function scores. The patients
were initially recruited to a longitudinal study designed to evaluate
the trajectory of recovery and the inter-relationships of symptoms,
activity limitations and participation restrictions in people under-
going primary TKR for OA of the knee13. Eligibility criteria included
age of 18 years or older who had English ﬂuency sufﬁcient for
completion of (PROs) and consent to participate. Participants,
recruited from ﬁve tertiary care centres, completed a battery of
questionnaires pre-surgery and 12 months post surgery.
The sample demographics (Table I) are typical of those receiving
TKR and, on average, there were large and statistically signiﬁcant
improvements for the group from pre-surgery to 1-year follow-up.Table I
Sample characteristics (n ¼ 494) and WOMAC pain and function scores
Characteristic
% Female 65.4
Age (mean, range in years) 64.9 (35e88)
Pre-surgery WOMAC pain (mean, range)* 10.4 (0e20)
Pre-surgery WOMAC function (mean, range)* 33.8 (3e68)
1-year post surgery WOMAC pain (mean, range) 3.4 (0e18)
1-year post surgery WOMAC function (mean, range) 14.0 (0e68)
* WOMAC pain subscale possible score range is 0e20 where 0 represents no pain
and function subscale possible range is 0e68 where 0 represents no functional
limitations.Participants were classiﬁed as having achieved an important
improvement on the pain subscale based on achieving a change
score of at least 7 points (of 20 points total) for WOMAC pain from
pre-surgery to 1 year post-surgery, a time when recovery is
accepted to have stabilized and maximized for most people13. For
function, participants achieved an important difference if the
change score was 22 points or greater (of a total of 68) from pre-
surgery to 1 year post-surgery. As our cohort included patients
from similar hospitals, we used the 1-year clinically important
difference values published by Chesworth et al. 11 (and used by
Alzahrani et al. in their study of TKR)9.
We calculated the proportion of people who could not achieve
important change based on both the pre-surgery pain and function
score (i.e., for pain with a score range of 0e20, the MCID value used
was 7 and from functionwith a score range of 0e68 the MCID value
used was 22 points). To demonstrate if baseline score affected
achieving an important change, we calculated and compared the
proportion achieving an important change in each of pain and
function based on tertiles of the pre-surgery pain and function
subscale score. Additionally, we evaluated whether satisfaction
with outcome varied in these three groups for each of pain and
function based on the response to a question asking how satisﬁed
the individual was with the outcome of their surgery (response
ranging fromvery dissatisﬁed to very satisﬁed). We anticipated that
if people did not achieve an important improvement, considering
pain and function subscales separately, there would be a tendency
for them to be less satisﬁed with their surgical outcome assuming
satisfaction is also a surrogate of efﬁcacy. We did not evaluate
important deterioration as few people having TKR (5% or less)
report worsening of pain and function11,12.
Response to treatment with TKR
Of the 483 people, 54.7% (n ¼ 264) achieved an important
improvement in pain (7 or more points improvement of 20) and
40.4% (195 of 486) achieved important improvement in function
(22 or more points improvement of 68) at 1 year after surgery. Of
those who did not achieve an important improvement in pain, 139
had a baseline pain score below 7 points and 155 had a baseline
function score below 22 such that these individuals did not have
potential to achieve important change or to be classiﬁed as
a responder prior to their surgery. That is, 28.8 % (139/483) of the
total sample were pre-determined prior to surgery to be a non-
responder based on their pre-surgery pain score. This proportion
was 31.9% for WOMAC function.
Dividing the sample into tertiles based onpre-surgery pain score,
Table II shows that the proportion of responders increased as the
baseline score increased (i.e., those with more pain and functional
disability pre-surgery were more likely to achieve important
improvements in pain and function). From lowest to highest pre-
surgery pain tertile (high is worse pain), 30.5, 66.7 and 74.3%
respectively achieved important change (P < 0.0001). We also note
that there is a signiﬁcantly higher proportion of females with worse
pain at baseline (P ¼ 0.0127) and that while there is a statistically
signiﬁcant difference in age across the tertiles, this is likely not
meaningful clinically. Therewas no statistically signiﬁcant difference
in satisfaction across tertiles of baseline score. Among those unable
to achieve a MCID for pain, 64.9% reported being very satisﬁed. The
equivalent estimate for physical functionwas 65.2%. The proportions
reported across tertiles for both outcomes were similar.
Similarly, there was a statistically signiﬁcant difference
(P < 0.0001) in the proportion who achieved an important
improvement in function, 4.7, 47.5 and 67.4% respectively, with
those with more functional problems pre-surgery more likely to
achieve important improvement. A higher proportion of females
Table II
Sample characteristics and achievement of clinically important improvement by tertiles of pre-surgery WOMAC pain and function score
Less pre-surgery pain More pre-surgery pain
WOMAC pain
Tertile score range Tertile 1 (0e9) Tertile 2 (10e12) Tertile 3 (13e20) P-value*
n (%) 188 (38.9) 161 (33.3) 134 (27.4)
Pre-surgery pain (mean, mean percent
change of total score)
6.9 (34.5%) 11.0 (55.0%) 14.6 (73.0%) <0.0001
% Female 57.6 66.5 73.1 0.0127
Age (mean, range in years) 66.7 (41e88) 65.7 (38e88) 61.3 (44e87) <0.0001
% Attaining important change (7/20) 30.5 66.7 74.3 <0.0001
% Very satisﬁed 64.3 62.9 66.7 0.8446
% Very dissatisﬁed 4.1 3.5 3.6
Less pre-surgery functional problems More pre-surgery functional problems
WOMAC function
Tertile score range Tertile 1 (3e28) Tertile 2 (29e39) Tertile 3 (40e68) P-value*
n (%) 161 (33.1) 157 (32.3) 168 (34.6)
Pre-surgery function (mean, mean percent
change of total score)
19.6 (28.8%) 34.1 (50.1%) 47.3 (69.5%) <0.0001
% Female 53.4 63.1 77.4 0.1375
Age (mean, range in years) 66.0 (35e86) 64.8 (41e88) 63.8 (37e87) <0.0001
% Attaining important change (22/68) 4.7 47.5 67.4 <0.0001
% Very satisﬁed 69.6 65.4 58.3 0.1121
% Very dissatisﬁed 3.4 2.2 5.6
* Chi-square test, ANOVA, or KruskaleWallis test as appropriate to data.
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There was no statistically signiﬁcant difference in satisfaction with
outcome based on pre-surgery function score.Implications and recommendations
These data demonstrate that deﬁning individuals as non-
responders to treatment based on a single value MCID without
consideration of the potential effect of the pre-intervention PRO
score may result in a signiﬁcant proportion of individuals being
misclassiﬁed as having received no beneﬁt from treatment. They
reinforce the ﬁndings of Stratford et al. in people treated with
physiotherapy for low back pain7 and Tubach et al. in people treated
medically with OA14. Tubach has suggested that the MCID be
calculated for the tertiles of the baseline score as a more accurate
depiction of response across the range of a given PRO14. The
broader implications of deﬁning response to treatment using
a single value MCID without consideration of baseline score,
including ceiling effects and possible regression to the mean, in
terms of misclassiﬁcation bias will only be known as clinicians and
scientists evaluate this phenomenon in additional work.
As an alternative to the MCID, The Patient Acceptable Symptom
State (PASS), threshold values that must be achieved to have an
acceptable outcome, is a measure of response that is less sensitive
to the baseline PRO score15. However, the baseline score impact is
predicated on whether those who have PRO scores that do not
exceed the threshold are included in the sample under study (i.e.,
the state may be acceptable but if there is an opportunity to be even
better an individual may choose additional treatment.) More recent
work by Beaton et al. evaluating response to treatment using
a diagnostic testing approach demonstrated that using a combined
MCID and ﬁnal status (PASS) approach had greatest accuracy
(sensitivity and speciﬁcity) and clinical sensibility as compared to
the MCID or PASS alone16. Additionally, our group showed that the
relationship of prior status and change in status of one construct
(e.g., pain) impacted another construct (e.g., function and or higher
demand activities such as those required for social role participa-
tion)13 such that multiple important constructs of outcome need to
be considered simultaneously.In a clinical context with individual patients, there might be
a temptation to suggest that people withminimal symptoms and or
disability should not be the group targeted for intervention be it
joint replacement surgery or another disease and intervention.
However, clinicians often are balancing a number of clinical and
patient characteristics in providing advice for and implementation
of treatment and PRO scores are not routinely part of the decision-
making process. This is demonstrated in joint replacement where
PROs including such constructs as pain and function alone have not
been discriminating in deciding who is recommended to receive
joint replacement; it is accepted that the decision to recommend
such surgery includes additional patient considerations17. There-
fore, clinical cohorts likely will continue to include patients with
minimal symptoms and disability. Irrespective, by considering
surgery for those who have only more pain and functional limita-
tions on ameasure or restricting cohorts to those who are generally
worse, then by design alone a larger proportion would achieve an
MCID, suggesting the interventionwas favourable, but with little, if
any, effect on level of patient satisfaction.
In summary, this work has demonstrated that using a single
value MCID for a PRO summary score or PRO subscale to determine
response to treatment when the sample includes individuals who
could not achieve important improvement based on their pre-
treatment status leads to misclassiﬁcation bias given that the
proportion of individuals who are satisﬁed with their results.
Future research needs to focus on advancing methodology for
accurately deﬁning criteria for response to treatment. In the
interim, given that many PROs have MCID values that have been
determined without considering the baseline score, we recom-
mend creating a third category of response to identify those who
cannot achieve response prior to intervention to understand
how the baseline score impacts the interpretation of the study
results.
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